GREAT-2 is a clinical trial to test a new treatment for bronchiectasis.
People with bronchiectasis frequently get chest infections which are difficult to treat. Approximately one third of people with bronchiectasis become infected with a bacteria called Pseudomonas aeruginosa (P. aeruginosa).
The purpose of this trial is to test whether an intravenous infusion drip containing a new drug called Gremubamab can reduce the amount of infection with P. aeruginosa.
The trial is being Sponsored by the University of Dundee & NHS Tayside and is being managed by Tayside Clinical Trials Unit.
![](https://sites.dundee.ac.uk/great-2/wp-content/uploads/sites/201/2023/02/VitalBE-Footer-1024x134.png)